Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, Large B-Cell, Diffuse 28Leukemia, Myeloid, Acute 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 23Lymphoma 22Small Cell Lung Carcinoma 20Burkitt Lymphoma 19Lymphoma, Non-Hodgkin 18Lung Neoplasms 13Recurrence 12Neuroblastoma 12Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Congenital Abnormalities 12Myelodysplastic Syndromes 11Lymphoma, Follicular 11Brain Neoplasms 10Hodgkin Disease 9Carcinoma, Non-Small-Cell Lung 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Accelerated Phase 8Leukemia, Monocytic, Acute 8Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Blast Crisis 8Sarcoma 7Neoplasms 7Myeloproliferative Disorders 7Multiple Myeloma 7

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × Etoposide × Clear all
NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled 17 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡